Pharma-Bio Serv, Inc. PBSV
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.48M | 9.11M | 8.82M | 9.00M | 9.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.48M | 9.11M | 8.82M | 9.00M | 9.18M |
| Cost of Revenue | 6.42M | 6.16M | 5.96M | 6.09M | 6.30M |
| Gross Profit | 3.07M | 2.95M | 2.86M | 2.91M | 2.89M |
| SG&A Expenses | 3.22M | 3.34M | 3.50M | 3.55M | 3.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.64M | 9.51M | 9.46M | 9.64M | 9.84M |
| Operating Income | -154.90K | -397.00K | -640.00K | -637.70K | -658.50K |
| Income Before Tax | 269.10K | 71.20K | -67.30K | -94.10K | -113.20K |
| Income Tax Expenses | 17.50K | 9.60K | 8.70K | 6.20K | -29.20K |
| Earnings from Continuing Operations | 0.25 | 0.06 | -0.08 | -0.10 | -0.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 251.60K | 61.50K | -76.10K | -100.50K | -84.30K |
| EBIT | -154.90K | -397.00K | -640.00K | -637.70K | -658.50K |
| EBITDA | -97.00K | -337.00K | -574.80K | -577.90K | -608.60K |
| EPS Basic | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 91.65M | 91.68M | 91.71M | 91.77M | 91.79M |
| Average Diluted Shares Outstanding | 91.68M | 91.71M | 91.74M | 91.79M | 91.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 682.67% | 2,792.85% | -2,260.05% | -1,711.34% | -2,040.21% |